Cinclus Pharma Holding AB (publ)

OM:CINPHA Stock Report

Market Cap: SEK 847.2m

Cinclus Pharma Holding Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:CINPHA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Jun 24BuySEK 32,500Peter UngeIndividual1,000SEK 32.50
20 Jun 24BuySEK 110,670Anders OhbergIndividual2,635SEK 42.00

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CINPHA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders5,219,52111.2%
Private Companies8,413,27418.1%
Institutions10,096,40821.7%
General Public22,808,58649%

Dilution of Shares: CINPHA only recently listed within the past 12 months

Top Shareholders

Top 22 shareholders own 50.99% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.48%
Trill Impact Ventures Pharma 1 AB
3,483,125SEK 63.4m0%no data
7.41%
Fourth Swedish National Pension Fund (AP4)
3,448,568SEK 62.8m0%0.02%
6.55%
BidCo af 6. december 2018 AB
3,048,629SEK 55.5m0%no data
5.03%
Movestic Fonder AB
2,341,756SEK 42.6m0%3.4%
4.42%
Linc AB
2,059,122SEK 37.5m0%2.18%
4.35%
Peter Unge
2,022,075SEK 36.8m0%no data
4.1%
Kjell Andersson
1,908,000SEK 34.7m0%no data
4.04%
Estate Of Mikael Dahlström
1,881,520SEK 34.3m0%no data
2.23%
Lennart Hansson
1,037,071SEK 18.9m0%no data
1.93%
Eir Ventures
898,750SEK 16.4m0%100.0%
1.28%
Arctic Asset Management AS
595,000SEK 10.8m0%0.08%
0.86%
AXA Investment Managers S.A.
400,000SEK 7.3m0%no data
0.54%
DNB Asset Management AS
250,000SEK 4.6m0%no data
0.19%
Torbjörn Koivisto
87,285SEK 1.6m0%no data
0.17%
Christer Ahlberg
80,000SEK 1.5m0%no data
0.12%
Clay Asset Management
55,000SEK 1.0m0%0.16%
0.1%
Helena Levander
46,780SEK 851.6k0%no data
0.099%
SEB Investment Management AB
45,924SEK 836.0k51.1%no data
0.045%
Wenche Rolfsen
20,800SEK 378.6k0%no data
0.02%
Anders Ohberg
9,510SEK 173.2k0%no data
0.017%
Maria Engstrom
8,000SEK 145.6k0%no data
0.0049%
Mercer Global Investments Europe Limited
2,288SEK 41.7k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/28 05:29
End of Day Share Price 2025/01/28 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cinclus Pharma Holding AB (publ) is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oscar Haffen LammBryan Garnier & Co
Kevin SuleRedeye